Business context and reporting period
The supplied filing is Oculus Innovative Sciences, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2015 (its fiscal first quarter), not a filing for Sonoma Pharmaceuticals, Inc. The company develops and markets dermatology and advanced tissue-care products based on its Microcyn technology, as well as laboratory testing services. Financial amounts below are in U.S. dollars; unless stated otherwise, figures are in millions.
Financial performance and position
| Metric | Quarter ended June 30, 2015 | Prior-year quarter or comparison |
|---|---|---|
| Revenue | $3.680 | $3.392; up 8% |
| Gross profit | $1.873; 50.9% of revenue | $1.906; 56.2% of revenue |
| Operating expenses | $4.184 | $3.420 |
| Operating loss | $(2.311) | $(1.514) |
| Net loss | $(2.340); $(0.15) per share | $(0.070); $(0.01) per share |
| Cash used in operations | $(2.585) | $(1.346) |
| Cash and cash equivalents | $8.752 at June 30 | $6.136 at March 31, 2015 |
| Working capital | $10.534 at June 30 | $7.066 at March 31, 2015 |
| Total liabilities | $3.069 | $2.994 at March 31, 2015 |
Product revenue rose 37% to $2.916 million, while licensing fees and royalties fell 57% to $0.447 million; service revenue increased to $0.317 million from $0.222 million. Cash provided by investing activities was $4.378 million, principally from selling the company’s remaining Ruthigen shares for $4.538 million, partly offset by equipment purchases and a banker fee. Financing provided $0.827 million, including $0.879 million net proceeds from at-the-market (ATM) share sales. The balance sheet reports a $0.035 million current portion of long-term debt; it shows no separate noncurrent debt line.
Changes versus the prior comparable period
- Revenue increased by $0.288 million, but gross profit declined by $0.033 million as total cost of revenues rose faster than sales.
- U.S. product revenue increased 122% to $0.787 million and Latin American product revenue increased 43% to $1.558 million. Europe and rest-of-world product revenue declined 15% to $0.571 million; management cited currency weakness and lower sales in some markets.
- Licensing and royalty revenue declined mainly after termination of the Innovacyn agreement and lower Exeltis unit volume. Innovacyn-related revenue was $0.020 million versus $0.528 million a year earlier.
- SG&A rose 25% to $3.717 million, primarily due to dermatology sales-force hiring and product launches. Net loss widened substantially, reflecting higher SG&A and a $0.059 million derivative-liability revaluation loss versus a $1.478 million gain in the prior-year quarter.
- Operating cash use increased, including a $1.052 million increase in accounts receivable associated with higher sales on payment terms.
Outlook, risks and unusual items
- Management expected cash to fund working-capital needs and ongoing sales, marketing and R&D efforts for at least 12 months, but anticipated continued losses and said additional capital may be needed for longer-term development and market expansion. Management cautioned that funding is not assured; absent funding, the company may reduce costs and curtail R&D.
- Management expected R&D expense to remain relatively flat over the following year and SG&A to remain within the then-current range over the next several quarters. It described plans for dermatology launches, including a scar product it intended to launch within 12 months, and an international post-laser product launch planned for fall 2015. These are forward-looking statements, not reported outcomes.
- Microcyn products had U.S. medical-device clearances, but the company said it lacked approval to market Microcyn as a drug in the United States. It said pivotal drug trials would be delayed until a strategic partner or other funding was secured.
- One customer accounted for 53% of quarterly revenue; two customers represented 57% and 11% of accounts receivable at quarter-end. This creates significant customer and collection concentration.
- Exeltis alleged breach of an exclusive distribution agreement relating to Alevicyn gel. The company disputed the claim, intended to defend it, and recorded no loss accrual; it acknowledged that an unfavorable outcome could harm results or financial position.
- The company sold its remaining Ruthigen shares for $4.538 million, recorded a $0.059 million loss from warrant derivative remeasurement, and continued ATM equity sales. It sold 724,100 additional shares after quarter-end through August 4 for $1.121 million net proceeds, adding to potential shareholder dilution.
- Stockholders approved authority for a possible 1-for-5 to 1-for-9 reverse split; the board had not authorized one as of the filing. The company disclosed no material change to previously reported risk factors and stated that disclosure controls were effective at a reasonable-assurance level.
Important facts for investors to verify
- Confirm the issuer: the filing identifies Oculus Innovative Sciences, Inc., whereas the request metadata names Sonoma Pharmaceuticals, Inc.
- Check subsequent filings for actual revenue, margins, cash burn and whether the stated 12-month liquidity expectation held.
- Track customer concentration, receivable collections and regional revenue trends, particularly Latin America and Europe.
- Verify the outcome of the Exeltis dispute, planned product launches, regulatory progress and any strategic partner or funding for clinical trials.
- Review subsequent equity issuance, dilution, warrant accounting and any board action on the approved reverse-split authority.